"Triple-TEN" in the treatment of acute ocular complications from toxic epidermal necrolysis.
OBJECTIVE
Toxic epidermal necrolysis (TEN) is a devastating form of Stevens-Johnson syndrome (SJS) with acute and chronic ocular complications. We present a novel aggressive combination strategy, termed "Triple-TEN", for the management of acute ocular TEN designed to minimize the risk of chronic, blinding sequelae.


METHODS
Two patients with life-threatening TEN accompanied by severe ocular surface defects and fulminant symblephara formation underwent "Triple-TEN" management of their acute ocular disease under aseptic techniques in the critical care setting, after failed treatment with intensive topical therapy and surgical division of symblephara. The Triple-TEN protocol comprises (1) subconjunctival triamcinolone (Kenalog 20 mg) administered into each of the fornices to curb the local inflammatory response without compromising systemic immunity, (2) placement of amniotic membrane tissue mounted on a polycarbonate skirt (ProKera) over the corneal and limbal regions to facilitate reepithelialization of the ocular surface, and (3) insertion of a steeply curved acrylic scleral shell spacer (Technovent, SC21) to vault the lids away from the globe providing a barrier to symblephara formation.


RESULTS
In both cases, ocular surface inflammation resolved within 4 weeks with no progression of conjunctival cicatrization or evidence of limbal epithelial stem cell failure at 1 year follow-up. There were no long-term complications of the Triple-TEN regimen.


CONCLUSIONS
Aggressive treatment with the Triple-TEN protocol for acute ocular TEN resistant to first-line therapy, may help prevent long-term blinding sequelae.
Academic Unit of Ophthalmology, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham and Midland Eye Centre, Birmingham, United Kingdom.
Paul J
PJ
Tomlins
Manoj V
MV
Parulekar
Saaeha
S
Rauz
D000180:Acrylic Resins; D000208:Acute Disease; D000293:Adolescent; D001684:Biological Dressings; D003131:Combined Modality Therapy; D003231:Conjunctivitis / Q000209:etiology / Q000628:therapy*; D005141:Eyelid Diseases / Q000517:prevention & control; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D011076:Polycarboxylate Cement; D019736:Prostheses and Implants; D013262:Stevens-Johnson Syndrome / Q000150:complications* / Q000209:etiology / Q000628:therapy*; D014222:Triamcinolone Acetonide / Q000627:therapeutic use*
D000180:Acrylic Resins; D005938:Glucocorticoids; D011076:Polycarboxylate Cement; C005506:polycarbonate; D014222:Triamcinolone Acetonide